A Polygenic Risk Score Assessment Reveals More Screening Participants with Clinically Significant Prostate Cancer Than Those Who Would Be Identified with PSA or MRI By Ogkologos - April 30, 2025 609 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BARCODE1 study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR Blood Test Accurately Detects Early-Stage Pancreatic Cancer May 10, 2024 Duration of Bevacizumab Maintenance of 15 Months Remains the Standard in... November 16, 2022 Tecartus Becomes First CAR T-Cell Therapy Approved for Adults with ALL November 10, 2021 Primary Tumour Resection Does Not Prolong OS in Patients with Treatment-Naïve... March 7, 2024 Load more HOT NEWS Sacituzumab Govitecan Demonstrates Overall Survival Benefit Over Chemotherapy in Patients with... Can cancer cells communicate? ΚΑΡΚΙΝΟΣ ΘΥΡΕΟΕΙΔΟΥΣ Tattoo Ink May Show Up as Suspicious Spots in Lymph Nodes...
